Novalgin (Metamizole Sodium Monohydrate)

Metamizole sodium monohydrate works by inhibiting cyclooxygenase enzymes, which reduces the production of prostaglandins. Lower prostaglandin levels decrease peripheral pain signaling and reset the hypothalamic set‑point for temperature, providing analgesic and antipyretic effects.

The specific dose of Novalgin is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal function. Healthcare professionals tailor the regimen to achieve optimal pain relief or fever control while minimizing risk.

Safety data for metamizole during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Novalgin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Novalgin belongs to the pyrazolone class, offering strong analgesic and antipyretic activity similar to NSAIDs but with a distinct safety profile. Unlike some NSAIDs, it has a lower risk of gastrointestinal ulceration but carries a rare risk of agranulocytosis, which must be weighed against alternatives.

Novalgin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container remains tightly closed to maintain stability.

Novalgin is supplied as a rectal formulation, typically a suppository. The healthcare professional inserts the suppository into the rectum, where it dissolves and is absorbed, providing rapid systemic analgesic and antipyretic effects.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, rash, or breathing difficulty, and treatment should be stopped immediately if these occur.

Novalgin should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, in patients with severe bone‑marrow suppression, and in those taking other pyrazolone‑containing medications. Caution is also advised for patients with severe renal impairment or a history of severe allergic reactions.